• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    4D Molecular Therapeutics Inc (NQ: FDMT )

    15.83 -2.37 (-13.02%)
    Streaming Delayed Price Updated: 1:36 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,152,613
    Open 18.20
    Bid (Size) 15.82 (1)
    Ask (Size) 15.84 (5)
    Prev. Close 18.20
    Today's Range 15.65 - 18.21
    52wk Range 9.440 - 36.25
    Shares Outstanding 42,052,980
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Peeling Back The Layers: Exploring 4D Molecular Therapeutics Through Analyst Insights
    Via Benzinga

    Performance

    YTD
    -25.51%
    -25.51%
    1 Month
    -33.49%
    -33.49%
    3 Month
    -37.43%
    -37.43%
    6 Month
    -10.82%
    -10.82%
    1 Year
    -12.73%
    -12.73%

    More News

    Read More
    FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    Assessing 4D Molecular Therapeutics: Insights From 7 Financial Analysts
    Via Benzinga
    Analyst Expectations For 4D Molecular Therapeutics's Future
    Via Benzinga
    4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate
    Via Benzinga
    Why ASLAN Pharmaceuticals Shares Are Trading Lower By Over 38%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Via Benzinga
    4DMT Announces Positive Phase 2 PRISM Interim Results for Intravitreal 4D-150 in a Broad Wet AMD Population Affirming Favorable Safety Profile and Robust Clinical Activity
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Announces FDA Clearance of IND Application for 4D-175 Genetic Medicine for the Treatment of Geographic Atrophy
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Present Initial Interim 24-week Landmark Analysis from the 4D-150 Phase 2 PRISM Population Extension Cohort in a Broad Wet AMD Population at ASRS and Host a Corporate Webcast
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside
    Via Benzinga
    Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Intraday Session
    Via Benzinga
    4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Modulator-Ineligible/-Intolerant Cystic Fibrosis at 47th European Cystic Fibrosis Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Participate in Upcoming Investor Conferences
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 47ᵗʰ European Cystic Fibrosis Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    FDMT Stock Earnings: 4D Molecular Therapeutics Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT to Participate in Upcoming Investor Conference
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    4DMT Announces Presentations at ARVO 2024 Annual Meeting
    From 4D Molecular Therapeutics, Inc.
    Via GlobeNewswire
    To The Moon! A Look Inside An ETF Focused On Companies At The Cutting Edge Of Innovation
    Via Benzinga
    Topics ETFs
    4D Molecular Therapeutics Outlines Pivotal Development Plans For Cystic Fibrosis, Rare Inherited Disease
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.